treated patients vary widely from one study to the next (for review see Kane et al, 1984) . In a survey of 56 studies a mean prevalence of 2O% was found (Kane & Smith, 1982) . The most consistently reported risk factor is age, older patients being at greater risk (Waddington & Youssef, 1988) . Women are probably at greater risk than men, especially of developing more severe forms of the disorder (Smith et al, 1978; Kane & Smith, 1982) . Doseâ€"response curves for tardive dyskinesia (TD) have in general not been demonstrated. Waddington & Youssef (1986) could find no relationship between the development of TD and either the duration or vigour of treatment with neuroleptics.
It has been suggested that patients with affective illness are at greater risk of developing TD than are patients with schizophrenia (Kane et a!, 1980). As a result of this, a monograph published by the American Psychiatric Association recommends that patients with bipolar affective disorder should not be prescribed long-term neuroleptic medication except in rare circumstances (Gardos & Casey, 1984) .
Lithium, which is widely used in the prophylaxis of bipolar affective disorder, has, however, been reported as effective in the management of TD (Prange et a!, 1973; Reda et a!, 1975; Gerlach et a!, 1975) . We decided to examine further the prevalence of tardive dyskinesia in bipolar out-patients, con centrating in particular on differences between patients taking lithium and those for whom it had never been prescribed.
Method
The study population consisted of 40 out-patients aged 30â€"60 years,all of whom had a DSMâ€"III diagnosisof 
Results
The overall prevalence of TD was 225%, with no significant gender difference. Three of 16 males had developed the dis order, and 6 of 24 females. Prevalence of the disorder increased with age (Table I) . Six of 11 patients between 50 and 60 years had significant dyskinesia, while only one patient under 40 years showed evidence of the disorder. The mean AIMS score of the patients with TD was 8.6 (s.d.
2.3).
Patients with and without TD did not differ in terms of duration of illness, but those patients with TD had significantly more psychiatric admissions (Mann Whitney U= 19.5, P@0.O5). Seven of the nine TD patientswere currently on lithium, while 22 of the 32 patientswithoutTD wereon lithium (Table II) . The two groupsdifferedsignificantly in termsof durationof lithium therapy, with TD patients on lithium for considerably greaterperiodsof time (Mann-WhitneyU=26.4, P@0.05).
Groups did not differ in current serum lithium levels, the duration of neuroleptic therapy, or the current neuroleptic dosage. forms of affective disorder which are less easily stabilised. When the pharmacological histories of patients with and without TD are compared, the most obvious difference between the groups is the fact that patients with TD had longer durations of lithium exposure. This may indicate that lithium exposure is one of many variables leading to the genesis of TD in patients with bipolar affective disorder, or alternatively it may indicate that a subgroup of bipolar patients are particularly resistant to treatment and biologically prone to the develop ment of TD. Much of the literature to date would 
P@O.O5.

Discussion
A prevalence of 22.5% TD in bipolar patients would indicate that the disorder is no more common in such patients than it is in schizophrenics. This is in contrast to the fmdings of Rush et a! (1982) , who found a prevalence of 64% in such patients, and those of Waddington & Youssef (1988) , who found a prevalence of 40%. Our low figure may be partly explained by the fact that we excluded patients over 60 years of age, as orofacial dyskinesia even in the absence of neuroleptics is high in this group (Klawans & Barr, 1982 (1984) , who suggest that severe TD is common in bipolar patients. The clear-cut increase in the prevalence of TD with age is in keeping with previous findings (Kane & Smith, 1982; Waddington et a!, 1985; Waddington & Youssef, 1988) , asis thefactthatpatients with and without TD do not differ in terms of duration of exposure to neuroleptics or current neuroleptic dosage. It is perhaps surprising that average daily neuroleptic intake is so high in a group of bipolar patients (Table II) . We are unable to explain this definitively.
The sample is representative of our bipolar affective disorder out-patients, and the relatively high neuroleptic intake may be a re flection of prescribing patterns in the district. The findingthat patientswith TD tendto havemore psychiatric admissions might suggest more virulent
